

Amendments to the Claims under 37 C.F.R. § 1.121

Claim 1 (previously presented): A trimeric polypeptide comprising three monomers, wherein each monomer comprises a cytokine binding domain and a tetranectin trimerising domain.

Claims 2-17 (cancelled).

Claim 18 (previously presented): The trimeric polypeptide according to claim 1, wherein the tetranectin trimerising domain comprises an amino acid sequence having at least 87% identity with the amino acid sequence of SEQ ID NO:81.

Claim 19 (previously presented): The trimeric polypeptide according to claim 1, wherein the tetranectin trimerising domain comprises an amino acid sequence having at least 92% identity with the amino acid sequence of SEQ ID NO:81.

Claim 20 (previously presented): The trimeric polypeptide according to claim 1, wherein the tetranectin trimerising domain comprises the amino acid sequence of SEQ ID NO:81.

Claim 21 (previously presented): The trimeric polypeptide according to claim 1, wherein at least one monomer comprises the amino acid sequence of SEQ ID NO:106 SEQ ID NO:108, or SEQ ID NO:107.

Claim 22 (previously presented): The trimeric polypeptide according to claim 1, further comprising a linker between the cytokine binding domain and the tetranectin trimerising domain.

Claim 23 (previously presented): A pharmaceutical composition comprising the trimeric polypeptide according to claim 1.

Claims 24-29 (cancelled).

Claim 30 (previously presented): A method of preparing a pharmaceutical composition comprising combining the trimeric polypeptide according to claim 1 with a pharmaceutically acceptable carrier.

Claims 31-34 (cancelled).

Claim 35 (currently amended): The trimeric polypeptide according to claim 20, wherein the cysteine residue at position number 50 of the amino acid sequence of SEQ ID NO:81 is ~~mutagenized~~ substituted with to a serine, threonine, methionine, or any other amino acid residue.